Vertex Pharmaceuticals (VRTX) Non-Current Deffered Revenue (2009 - 2017)
Vertex Pharmaceuticals (VRTX) posted quarterly Non-Current Deffered Revenue of $1.7 million for Q4 2017, down 73.97% year-over-year from $6.6 million in Q4 2016, and down 40.83% quarter-over-quarter from $2.9 million in Q3 2017.
Vertex Pharmaceuticals (VRTX) Non-Current Deffered Revenue (2009 - 2017) Analysis & Trends
Vertex Pharmaceuticals' Non-Current Deffered Revenue history runs 9 years deep, the most recent figure standing at $1.7 million for Q4 2017.
- In Q4 2017, Non-Current Deffered Revenue fell 73.97% year-over-year to $1.7 million; the TTM figure through Dec 2017 stood at $1.7 million (down 73.97% YoY), while the FY2017 annual figure was $1.7 million, down 73.97% from the prior year.
- Non-Current Deffered Revenue for Q4 2017 stood at $1.7 million, down from $2.9 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $90.3 million in Q1 2013, with the low at $1.7 million in Q4 2017.
- The 5-year median for Non-Current Deffered Revenue is $19.3 million (2015), against an average of $28.1 million.
- The sharpest annual moves came in 2013 and 2017: Non-Current Deffered Revenue decreased 22.28% in 2013, then sank 73.97% in 2017.
- Vertex Pharmaceuticals' Non-Current Deffered Revenue stood at $49.5 million in 2013, then plunged by 43.78% to $27.8 million in 2014, then tumbled by 65.07% to $9.7 million in 2015, then slumped by 31.73% to $6.6 million in 2016, then sank by 73.97% to $1.7 million in 2017.
- Business Quant data shows VRTX's Non-Current Deffered Revenue at $1.7 million in Q4 2017, $2.9 million in Q3 2017, and $4.2 million in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 1.73 Mn |
| Sep 30, 2017 | 2.92 Mn |
| Jun 30, 2017 | 4.16 Mn |
| Mar 31, 2017 | 5.74 Mn |
| Dec 31, 2016 | 6.63 Mn |
| Sep 30, 2016 | 6.56 Mn |
| Jun 30, 2016 | 7.41 Mn |
| Mar 31, 2016 | 8.49 Mn |
| Dec 31, 2015 | 9.71 Mn |
| Sep 30, 2015 | 17.50 Mn |
| Jun 30, 2015 | 21.02 Mn |
| Mar 31, 2015 | 24.00 Mn |
| Dec 31, 2014 | 27.81 Mn |
| Sep 30, 2014 | 34.72 Mn |
| Jun 30, 2014 | 38.11 Mn |
| Mar 31, 2014 | 43.89 Mn |
| Dec 31, 2013 | 49.46 Mn |
| Sep 30, 2013 | 77.35 Mn |
| Jun 30, 2013 | 84.07 Mn |
| Mar 31, 2013 | 90.30 Mn |